Medisights Pioneers AI for Near Real-Time Market Insights in Multiple Myeloma

NEW YORK, Sept. 16, 2026 /CourierPR/ -- Medisights, an AI-native platform for life sciences, has pioneered a groundbreaking methodology that captures near real-time market intelligence in complex diseases like multiple myeloma. The company's latest study demonstrates that purpose-built AI agents can navigate the intricate and rapidly evolving landscape of multiple myeloma, providing actionable insights that were previously unattainable through traditional market research methods.

Multiple myeloma is recognized as a highly complicated disease with constantly changing treatment practices. Historically, traditional qualitative primary market research has taken months to execute, leaving life sciences companies with outdated data. Medisights has drastically accelerated this timeline, compressing months of research into mere days and weeks, delivering near real-time market intelligence that empowers teams to act quickly.

The study, which aimed to answer critical industry questions, tested whether AI could keep companies up to date with deep information on outlier innovative practices and in near-real time. Furthermore, it sought to identify unmet needs that pharmaceutical companies in this space need to know about. The results were definitive, with Medisights' clinical-grade AI moderators conducting in-depth, adaptive, and highly humanized conversations with specialists. These interactions, which traditional market researchers would struggle to achieve, lasted 45 to 60 minutes, capturing the underlying logic behind prescribing behaviors and mapping geographical nuances in CAR-T referral pathways.

Key strategic insights and actionable market intelligence uncovered by the study include: - Proactive market access and insurance navigation: The study identified insurance authorization as a primary barrier to entry for in vivo CAR-T therapies. - Closing the mechanistic awareness gap: Intelligence revealed a significant knowledge gap among community oncologists who frequently conflate in vivo CAR-T with allogeneic or off-the-shelf ex vivo products, highlighting an urgent requirement for targeted medical education. - Value proposition and treatment-free intervals: Specialists confirmed that eliminating manufacturing wait times serves as the gateway to a meaningful treatment-free interval, establishing "speed-to-treatment" in rapidly progressing patients as the defining narrative for in vivo therapies over bispecifics. - Benchmarking efficacy expectations: Results demonstrated that clinical adoption hinges on anchoring in vivo efficacy directly to established ex vivo benchmarks, specifically MRD negativity rates, depth of response, and overall survival metrics.

Unlike generic AI agents, Medisights' agents are aligned with curated advanced clinical taxonomies, ensuring absolute fidelity to clinical facts. This breakthrough ensures that life sciences commercial teams, medical affairs, and field forces can now access a single, verifiable source of truth.